Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...
As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...
Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results